Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide for Opioid Use Disorder
NCT04199728Phase 2Completed
- Sponsor
- Penn State Health Milton S. Hershey Medical Center
- Start
- Oct 2021
- Primary completion
- Sep 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of liraglutide in opioid use disorder (OUD) (2 arms), sponsored by Penn State Health Milton S. Hershey Medical Center. Primary endpoints: Change in Self-reported Cue-elicited Drug Craving at Day 19 and Change in Ambient Drug Craving Over Time. Started Oct 2021; status: completed.
02
Drugs
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT04199728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04199728.